Detail akcie Enliven Therp Rg online

Business Summary: Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Enliven Therapeutics Inc revenues was not reported. Net loss increased 12% to $74M. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase of 10% to $85.4M, United States segment loss increase of 10% to $85.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.44 to -$1.38.